Immunotherapies – Genprex

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Keytruda® to Treat Non-Small Cell Lung Cancer

March 31, 2022Kalyn Dabbs Acclaim 2 Press Releases

Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

April 12, 2021Kalyn Dabbs Acclaim 2 Press Releases

Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).

Designed and Secured by Barsec